Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.”In the company’s words, NCT05504083 on ClinicalTrials.gov
- Tested for
- Hyperuricemia, Gout, Hyperuricemia or Gout
- Main trialPhase 2
- “This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.”In the company’s words, NCT05504083 on ClinicalTrials.gov
Other drugs for Hyperuricemia
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- Combined metabolic activatorsScandiBio Therapeutics AB · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SHR4640Hengrui · Phase 2
- PRX-115Protalix · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 18 May 2024 | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients | |
| Phase 2Completed | 31 Jul 2025 | Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout | |
| Phase 1/2Completed | 31 Dec 2021 | D-0120 Safety and PK/PD Study in China | |
| Phase 1Completed | 30 Mar 2020 | Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026